Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Etablierung von Fibroblasten-abgeleiteten Zelllinien aus Hautbiopsien von Patienten mit Immunschwäche- oder Immundysregulationsstörungen

Etablierung von Fibroblasten-abgeleiteten Zelllinien aus Haut-/Gewebebiopsien von Patienten mit Immunschwäche- oder Immundysregulationsstörungen

Background:

  • National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in this system can make a person sick.
  • To study the cells of patients who have problems with their immune systems, researchers would like to collect samples of skin cells from patients with immune system disorders and compare them with skin cells taken from healthy volunteers. By studying these cells, researchers hope to determine whether these cells can be modified to create a new kind of personalized gene therapy that would attempt to cure immune diseases in the future.

Objectives:

  • To obtain skin cells from patients with immune system disorders and from healthy volunteers for research and comparison purposes.

Eligibility:

  • Patients between the ages of 2 and 85 who have immune system disorders.
  • Healthy volunteers between the ages of 18 and 85.
  • Both groups will be selected from the eligible participants of existing NIH studies into immune system disorders.

Design:

  • Researchers may take up to two biopsies from participants arms, legs, abdomen, or back.
  • The biopsy site will be numbed with local anesthetic and cleaned before the sample is taken.
  • The punch skin biopsy needle will be inserted into the skin and rotated to remove a small circle of skin (approximately 1/4 to 3/8 of an inch across). The area will be closed with bandages or stitches, and then covered with a dressing. Any stitches will be removed in 7 to 10 days.
  • Tissue samples collected in the study will be stored for future research.

Studienübersicht

Status

Anmeldung auf Einladung

Bedingungen

Detaillierte Beschreibung

This protocol is designed as an adjunct to other National Institutes of Health (NIH) IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary immunodeficiency or immunodysregulation disorders. Patients deemed of sufficient research interest after review of outside medical records, clinical evaluation, and testing, may be invited to participate in this study. Healthy volunteers and relatives of patients will also be invited to participate as a source of control samples for research testing. After consent and enrollment into this study, skin punch biopsies will be obtained to establish dermal fibroblast cell lines for research studies directed at understanding the genetic and biochemical bases of these diseases. Cell lines will also be used to investigate the utility of induced pluripotent stem cells (iPS) for lymphocyte derivation and targeted gene correction. The nasal epithelial scrapings will be used for research purposes to grow out primary nasal respiratory epithelial cell lines. These cell lines will be used for functional studies by testing virus replication in them. These functional studies will allow us to identify new primary immunodeficiencies that may present primarily as recurrent or persistent lower respiratory tract virus infections. Results with the potential to impact medical care will be relayed to the referring physicians and where applicable patients will be referred to other appropriate NIH protocols for additional clinical evaluation and treatment.

The study will enroll up to 200 patients and healthy volunteers over the next 27 years.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

200

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Maryland
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • National Institutes of Health Clinical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre bis 85 Jahre (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Up to 150 patients with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders, and up to 50 healthy volunteers as controls. Patients and healthy volunteers, who are first evaluated under another NIAID protocol (such as 05-I-0213 or 06-I-0015) and others, may be offered the opportunity to participate in this protocol.

Beschreibung

  • INCLUSION CRITERIA:

Patients:

  1. To be enrolled in this study, a patient must be >=2 years of age but not >85 years of age,
  2. have a known diagnosis of primary immunodeficiency or immunodysregulation (or be a blood relative of such as patient),
  3. be concurrently enrolled on an NIH IRB approved NIAID protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015

Patient Relative: To be enrolled in this study, a patient relative must be:

  1. A biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, sibling, children, grandparents, aunts, uncles and first cousins.

    a. A minor relative of the proban participant must demonstrate that they are asymptomatic carriers or are at risk for the disease

  2. be concurrently enrolled on an NIH IRB approved protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015.

  3. Greater than or equal to 8 years of age but not greater than 85 years of age,

Healthy Volunteers:

To be enrolled in this study, a normal volunteer must fulfill all of the following criteria:

  1. Be enrolled on protocol 05-I-0213.
  2. Be a healthy adult of either sex and between ages of 18 years and 85 years

EXCLUSION CRITERIA:

Patients or the Patient Relative are not eligible to be in this trial if::

  1. Platelet count less than 20,000/microL
  2. The individual is hemodynamically unstable because of acute bleeding.
  3. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study or limits the utility of the specimen to be obtained.
  4. For Nasal Scraping: a history of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies.

A Healthy Volunteer is not eligible to be in this trial if they:

  1. Areless than 18 years old or older than 85 years
  2. Weighs less than 110 pounds
  3. Are pregnant or breastfeeding
  4. Are receiving a chemotherapeutic agent(s) or has a malignancy
  5. Cannot avoid taking aspirin or non-steroidal anti-inflammatory medications during the 7 days preceding skin biopsy
  6. Have history of heart, lung, kidney disease, bleeding disorders, diabetes mellitus, chronic peripheral arterial or venous insufficiency, chronic diffuse skin conditions without uninvolved areas suitable for skin biopsy, poor skin healing, or keloid formation.
  7. Have been diagnosed as having viral hepatitis (B or C), human immunodeficiency virus (HIV), or a carrier for methicillin-resistant Staphylococcus aureus (MRSA)
  8. Hemoglobin measurement is less than 12.0 g/dL
  9. Platelet count less than 150,000/(micro)L
  10. PT greater than 15.0 seconds or PTT greater than 40 seconds
  11. Have a history of intravenous injection drug use or of engaging in high-risk activities for exposure to the acquired immunodeficiency syndrome (AIDS) virus.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: CROSS_SECTIONAL

Kohorten und Interventionen

Gruppe / Kohorte
Healthy Volunteers

Up to 50 subjects as healthy controls

Immunodeficiency

Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Generate fibroblast, dermal, or other skin-resident cell lines
Zeitfenster: Over the lifetime of the study

Obtain skin punch biopsies to generate fibroblast, dermal, or other skin-resident cell lines in patients who previously underwent HSCT. Cells may also be used for somatic cell hybridization, cell complementation, assessing fibroblast-specific innate immune responses, or other genetic techniques.

Over the lifetime of the study

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Helen C Su, M.D., National Institute of Allergy and Infectious Diseases (NIAID)

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Juni 2009

Studienanmeldedaten

Zuerst eingereicht

7. Mai 2009

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. Mai 2009

Zuerst gepostet (Geschätzt)

8. Mai 2009

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

27. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

26. Oktober 2026

Zuletzt verifiziert

2. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 090133
  • 09-I-0133

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

There isn't any data generated on this study that is relevant or shareable to any individual participant. Data obtained from iPS line growth is not medically actionable and therefor will not be reported back or shared with the participant.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .